Analysis of MFDS IND Approval Trends in August 2025

Overview

In August 2025 the Korean Ministry of Food and Drug Safety (MFDS) approved 50 investigational new drug (IND) clinical trial applications. The IND system evaluates whether a study drug has sufficient safety and scientific rationale before clinical testing. International regulatory advisers note that the Korean IND process has three stages—submission of documents, review by MFDS and approval with post‑approval obligations—and that the review usually takes around 30 working days, although the timeline can vary depending on dossier complexity. Applicants may request scientific advice before submission, and the MFDS oversees all matters relating to drug safety and quality.

Analysis of August approvals

The attached spreadsheet shows that 50 INDs were approved between 1 and 31 August 2025. Of these, 38 approvals (76 %) were for globally developed products and 12 approvals (24 %) were for locally developed products. By clinical phase there were 16 phase III trials, 11 phase II, 9 phase I, three phase IIa, three phase I/II, two phase IIb, two phase I/IIa, two phase Ib, one phase IIIb and one phase IV. Approvals were concentrated on 19 August (seven approvals) with five approvals each on 1 and 14 August, indicating sustained review activity despite the summer holiday period.

Leading sponsors and development region

The largest number of approvals came from IQVIA Korea Ltd. and MSD Korea Ltd., each with five approvals. They were followed by Fortrea Korea, PPD Development PTE Ltd. (three each) and Bayer Korea, AstraZeneca Korea, Novartis Korea, Medpace Inc., BMS Korea and Worldwide Clinical Trials Korea with two approvals each.

Top companies by approvals

The dominance of globally developed programs (38 approvals) underscores Korea’s role as an attractive hub for multinational clinical research. However, locally developed INDs (12 approvals) show that domestic biotech firms are progressing candidates into clinical stages, particularly phase III trials for diabetes and cardiovascular diseases.

Therapeutic areas and study characteristics

The approvals span cardiovascular diseases, metabolic disorders (diabetes and obesity), oncology (prostate and lung cancer), neuropsychiatric conditions and rare diseases. Key phase III approvals include BAY 94‑8862 for heart failure with left ventricular dysfunction, maridebart cafraglutide targeting obesity and atherosclerotic cardiovascular disease, IN‑B00009 for inadequately controlled type 2 diabetes, and xaluritamig for chemotherapy‑naïve metastatic castration‑resistant prostate cancer. The emphasis on pharmacological interventions rather than novel digital devices suggests that traditional therapeutics remain the mainstay of Korea’s clinical trial portfolio. Both multinational pipelines and home‑grown biotech assets illustrate the growing sophistication of the Korean clinical R&D ecosystem.

Regulatory environment and implications

Regulatory consultancies remark that Korea’s IND review is relatively fast, typically concluding within 30 working days, and that interactions with the MFDS are transparent. Nevertheless, sponsors must be prepared for post‑approval obligations such as reporting protocol amendments and safety updates. Companies should maintain robust data management systems and consider engaging experienced consultants to navigate overlapping regulations for pharmaceuticals, biologics and medical devices.

Conclusion and call to action

The August 2025 MFDS IND approval statistics reaffirm Korea’s appeal to domestic and international pharmaceutical and biotechnology communities. A high proportion of phase III studies signals that many pipelines are nearing commercialization. Our firm provides comprehensive regulatory and clinical trial consulting services covering IND preparation, submission and post‑approval management in Korea. We also publish a monthly newsletter summarizing the latest MFDS approvals and regulatory updates—please click the “Newsletter Subscription” button if you would like to receive it. If you are planning an IND submission or local trial execution, request a customized quote using the Quote Request link.